Evidence map›Paper›PMID 24688455›Full record

ArticleAdvanced functional materials2013

Inflammatory cytokines presented from polymer matrices differentially generate and activate DCs

Omar A Ali, Prakriti Tayalia, Dmitry Shvartsman, Sarah Lewin, David J Mooney

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Advanced functional materials, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.

0numbers the graph read from it
0cells of the map it votes in
33citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

33 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Article
  6. Frontiers in pharmacology · 2022
    Article
  7. Review
  8. Article
  9. Review
  10. Nanotechnology synergized immunoengineering for cancer.European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V · 2021
    Review
  11. Review
  12. Review
  13. Article
  14. Review
  15. Article
  16. Review
  17. Review
  18. Delivery technologies for cancer immunotherapy.Nature reviews. Drug discovery · 2019
    Review
  19. Synthetic immune niches for cancer immunotherapy.Nature reviews. Immunology · 2018
    Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Omar A AliWyss Institute for Biologically Inspired Engineering, Harvard University, Boston, MA.
Prakriti TayaliaWyss Institute for Biologically Inspired Engineering, Harvard University, Boston, MA ; School of Engineering and Applied Sciences, Harvard University, Cambridge, MA.
Dmitry ShvartsmanWyss Institute for Biologically Inspired Engineering, Harvard University, Boston, MA ; School of Engineering and Applied Sciences, Harvard University, Cambridge, MA.
Sarah LewinWyss Institute for Biologically Inspired Engineering, Harvard University, Boston, MA.
David J MooneyWyss Institute for Biologically Inspired Engineering, Harvard University, Boston, MA ; School of Engineering and Applied Sciences, Harvard University, Cambridge, MA.

Funding

Biomaterial based breast cancer vaccineR01EB015498 · NIBIB · HARVARD MEDICAL SCHOOL · PI MOONEY, DAVID J · 2013 to 2016
$1.5M
NIBIB NIH HHS R01 EB015498
6 · The paper itself

Abstract

During infection, inflammatory cytokines mobilize and activate dendritic cells (DCs), which are essential for efficacious T cell priming and immune responses that clear the infection. Here we designed macroporous poly(lactide-co-glycolide) (PLG) matrices to release the inflammatory cytokines GM-CSF, Flt3L and CCL20, in order to mimic infection-induced DC recruitment. We then tested the ability of these infection mimics to function as cancer vaccines via induction of specific, anti-tumor T cell responses. All vaccine systems tested were able to confer specific anti-tumor T cell responses and longterm survival in a therapeutic, B16-F10 melanoma model. However, GM-CSF and Flt3L vaccines resulted in similar survival rates, and outperformed CCL20 loaded scaffolds, even though they had differential effects on DC recruitment and generation. GM-CSF signaling was identified as the most potent chemotactic factor for conventional DCs and significantly enhanced surface expression of MHC(II) and CD86(+), which are utilized for priming T cell immunity. In contrast, Flt3L vaccines led to greater numbers of plasmacytoid DCs (pDCs), correlating with increased levels of T cell priming cytokines that amplify T cell responses. These results demonstrate that 3D polymer matrices modified to present inflammatory cytokines may be utilized to effectively mobilize and activate different DC subsets

Identifiers

PMID24688455
PMCPMC3968866

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.